1 / 12

Prostate Cancer Therapeutics Market Size, Share, Study 2019

Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 Report Overview Research Beam adds a report titled “Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019” that provides detailed information of the Prostate Cancer Therapeutics Market. The report is an excellent piece of study for investors who are looking towards the market. Summary GBI Research has released the pharmaceutical report “Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019”. The recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage patients with a number of options and increased survival times by a number of months. These recent approvals are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as the treatment algorithm shifts towards their first-line usage over Taxotere. Additionally, a very large late-stage pipeline is anticipated to produce a number of new market entrants which are superior to existing products. Overall, this is anticipated to drive rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019 at a CAGR of 10.1%. Get Full Details On: http://www.researchbeam.com/prostate-cancer-therapeutics-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019-market

MarkLesnar
Download Presentation

Prostate Cancer Therapeutics Market Size, Share, Study 2019

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 (Type, Mode of action, Crop Type and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020 • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@researchbeam.com Published on : Oct 2014

  2. Report Overview Research Beam adds a report titled “Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019” that provides detailed information of the Prostate Cancer Therapeutics Market. The report is an excellent piece of study for investors who are looking towards the market. Summary GBI Research has released the pharmaceutical report “Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019”. The recent approval of a number of highly effective drugs, including Zytiga and Xtandi, has provided late-stage patients with a number of options and increased survival times by a number of months. These recent approvals are anticipated to generate strong revenues during the forecast following increasing uptake by physicians as the treatment algorithm shifts towards their first-line usage over Taxotere. Additionally, a very large late-stage pipeline is anticipated to produce a number of new market entrants which are superior to existing products. Overall, this is anticipated to drive rapid market growth from $4.1 billion in 2012 to $8.0 billion by 2019 at a CAGR of 10.1%.

  3. Report Overview Scope - A brief introduction to prostate cancer, including the disease’s pathogenesis, risk factors, diagnosis, staging and treatment algorithms for each stage. - In-depth analysis of drugs available for the treatment of prostate cancer, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy. - Comprehensive review of the pipeline for prostate cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, program type. - Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action. Get Full Details On: http://www.researchbeam.com/prostate-cancer-therapeutics-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019-market

  4. Report Overview - Discussion of the licensing and co-development deals landscape in prostate cancer, Includes an analysis of licensing deals by stage of development, molecule type and mechanism of action. Also includes an analysis of both licensing and co-development deals by year and value and network maps of licensing and co-development deals. Reasons to buy - Understand the different levels of prostate cancer therapies, from early-stage prostate cacner to metastatic and castrate-resistant prostate cancer. - Understand the vast scope and diversity of the pipeline, including which molecule types and mechanisms of action are prominent. - Observe the trends in clinical trial duration and size amongst clinical Phases, between molecule types and mechanisms of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for prostate cancer therapeutics. - Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the prostate cancer therapeutics market.

  5. Table of Contents 1 Table of Contents 5 1.1 List of Tables 7 1.2 List of Figures 8 2 Introduction 9 2.1 Pathophysiology and Etiology 9 2.2 Epidemiology 11 2.3 Disease Progression 13 2.4 Treatment 15 3 Marketed Products 19 3.1 Hormonal Therapies 19 3.1.1 Zoladex (Goserelin) – AstraZeneca 19 3.1.2 Lupron Depot (Leuprolide acetate) – Abbvie21 3.1.3 Triptorelin 22

  6. Table of Contents 3.1.4 Firmagon (degarelix) – Ferring 22 3.1.5 Casodex (Bicalutamide) 23 3.1.6 Summary 234 Prostate Cancer Developmental Pipeline 33 4.1 Overall Pipeline 33 4.2 Mechanisms of Action 35 4.3 Clinical Trials 36 4.3.1 Attrition Rate 36 4.3.2 Enrollment 38 4.3.3 Duration 41 5 Market Forecast to 2019 47 5.1 Global 47 5.1.1 Treatment Usage Patterns 47

  7. Table of Contents 5.1.2 Market Size 49 5.2 North America 50 5.2.1 US 50 5.2.2 Canada 52 5.3 Five European Markets 54 5.3.1 Treatment Usage Patterns 54 5.3.2 Annual Cost of Therapy 56 5.3.3 Market Size 57 5.4 Japan 58 5.4.1 Treatment Usage Patterns 585.4.2 Market Size 59 Enquire About Report: http://www.researchbeam.com/prostate-cancer-therapeutics-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019-market/enquire-about-report

  8. List of Tables Table 1: Prostate Cancer Therapeutics, Prostate Cancer Risk Factors 10 Table 2: Prostate Cancer Therapeutics, Prostate Cancer Staging 13 Table 3: Prostate Cancer Therapeutics, Abbreviations 70 Table 4: Prostate Cancer Therapeutics, Sources for Heat Map 78 Table 5: Prostate Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 83 Table 6: Prostate Cancer Therapeutics, Global, All Pipeline Products (Preclinical/IND Filed), 2013 85 Table 7: Prostate Cancer Therapeutics, Global, All Pipeline Products (Phase I), 2013 94 Table 8: Prostate Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 97 Table 9: Prostate Cancer Therapeutics, Global, All Pipeline Products (Phase III/Pre-Registration), 2013 101 Table 10: Prostate Cancer Therapeutics, Global, All Pipeline Products (Undisclosed Stage of Development), 2013 103 Table 11: Prostate Cancer, Leading Eight Markets, Market Forecast, 2012–2019 103 Table 12: Prostate Cancer, US, Market Forecast, 2012–2019 104 Table 13: Prostate Cancer, UK, Market Forecast, 2012–2019 104

  9. List of Tables Table 14: Prostate Cancer, France, Market Forecast, 2012–2019 105 Table 15: Prostate Cancer, Germany, Market Forecast, 2012–2019 105 Table 16: Prostate Cancer, Italy, Market Forecast, 2012–2019 106 Table 17: Prostate Cancer, Spain, Market Forecast, 2012–2019 106 Table 18: Prostate Cancer, Japan, Market Forecast, 2012–2019 107 Table 19: Prostate Cancer, Canada, Market Forecast, 2012–2019 107 Request For Discount: http://www.researchbeam.com/prostate-cancer-therapeutics-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019-market/purchase-enquiry

  10. List of Figures Figure 1: Prostate Cancer Therapeutics: Percentage of Men Diagnosed with Prostate Cancer in the US, by Age, 2005–2009 11 Figure 2: Prostate Cancer Therapeutics: Average Number of New Cases and Age-Specific Incidence Rates per 100,000 Population, UK, 2008–2010 12 Figure 3: Prostate Cancer Therapeutics: Prostate Cancer Treatment Algorithm (Stages I and II) 15 Figure 4: Prostate Cancer Therapeutics: Prostate Cancer Treatment Algorithm (Stage III) 15 Figure 5: Prostate Cancer Therapeutics: Prostate Cancer Treatment Algorithm (Stage IV) 16 Figure 6: Prostate Cancer Therapeutics, Sales of Zoladex ($m), 2000–2012 20 Figure 7: Prostate Cancer Therapeutics, Sales of Lupron Depot ($m), 2009–2012 21 Figure 8: Prostate Cancer Therapeutics, Sales of Taxotere ($bn), 2004–2012 24 Figure 9: Prostate Cancer Therapeutics: Heat Map (mCRPC) 31 Figure 10: Market for Prostate Cancer, Global, Pipeline Overview, 2013 34 Figure 11: Market for Prostate Cancer, Global, Mechanisms of Action, 2013 35 Figure 12: Market for Prostate Cancer, Global, Clinical Trial Failure Rates, 2006–2013 36 Figure 13: Market for Prostate Cancer, Global, Clinical Trial Failure Rates (Molecule Type), 2006–2013

  11. Similar Market Studies • Published Reports • Neos Therapeutics, Inc. - Product Pipeline Review - 2014 • http://www.researchbeam.com/neos-therapeutics-inc-product-pipeline-review-2014-market • CureVac GmbH - Product Pipeline Review - 2014 • http://www.researchbeam.com/curevac-gmbh-product-pipeline-review-2014-market • arGEN-X BV - Product Pipeline Review - 2014 • http://www.researchbeam.com/argen-x-bv-product-pipeline-review-2014-market

  12. FOR MORE DETAILS Visit us at : http://www.researchbeam.com/ Stay With Us: 5933 NE Win Sivers Drive,#205, Portland, OR 97220United States • TELEPHONE: +1 (855) 711-1555E-MAIL: sales@researchbeam.com

More Related